IDH1 and central nervous system cancer: The latest version of the WHO glioma category released in 2016 has included the evaluation of molecular characteristics, such as isocitrate dehydrogenase (IDH) mutations, chromosome 1p/19q codeletion and RELA fusion positivity (Louis et al., 2016).